These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 7705443)

  • 1. Persistent oral dyskinesias in haloperidol-withdrawn neonatal 6-hydroxydopamine-lesioned rats.
    Huang NY; Kostrzewa RM
    Eur J Pharmacol; 1994 Dec; 271(2-3):433-7. PubMed ID: 7705443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent spontaneous oral dyskinesias in haloperidol-withdrawn rats neonatally lesioned with 6-hydroxydopamine: absence of an association with the Bmax for [3H]raclopride binding to neostriatal homogenates.
    Huang NY; Kostrzewa RM; Li C; Perry KW; Fuller RW
    J Pharmacol Exp Ther; 1997 Jan; 280(1):268-76. PubMed ID: 8996206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of oral and locomotor activity in chronic haloperidol-treated rats following cortical N-methyl-D-aspartate stimulation.
    Grimm JW; Kruzich PJ; See RE
    Pharmacol Biochem Behav; 1998 May; 60(1):167-73. PubMed ID: 9610939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-administration of progabide inhibits haloperidol-induced oral dyskinesias in rats.
    Kaneda H; Shirakawa O; Dale J; Goodman L; Bachus SE; Tamminga CA
    Eur J Pharmacol; 1992 Feb; 212(1):43-9. PubMed ID: 1555638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced oral activity response to A77636 in neonatal 6-hydroxydopamine-lesioned rats.
    Huang NY; Kostrzewa RM
    Eur J Pharmacol; 1994 Feb; 253(1-2):163-6. PubMed ID: 7912196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tiagabine inhibits haloperidol-induced oral dyskinesias in rats.
    Gao XM; Kakigi T; Friedman MB; Tamminga CA
    J Neural Transm Gen Sect; 1994; 95(1):63-9. PubMed ID: 7857587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development.
    Neal-Beliveau BS; Joyce JN
    Dev Psychobiol; 1998 May; 32(4):313-26. PubMed ID: 9589220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lifelong Rodent Model of Tardive Dyskinesia-Persistence After Antipsychotic Drug Withdrawal.
    Kostrzewa RM; Brus R
    Curr Top Behav Neurosci; 2016; 29():353-362. PubMed ID: 26472552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coenzyme Q10 does not prevent oral dyskinesias induced by long-term haloperidol treatment of rats.
    Andreassen OA; Weber C; Jørgensen HA
    Pharmacol Biochem Behav; 1999 Nov; 64(3):637-42. PubMed ID: 10548281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subchronic treatment with haloperidol and clozapine in rats with neonatal excitotoxic hippocampal damage.
    Lipska BK; Weinberger DR
    Neuropsychopharmacology; 1994 May; 10(3):199-205. PubMed ID: 7916917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol.
    Gao XM; Sakai K; Tamminga CA
    Neuropsychopharmacology; 1998 Nov; 19(5):428-33. PubMed ID: 9778664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dose-response characteristics of rat oral dyskinesias with chronic haloperidol or clozapine administration.
    Gao XM; Hashimoto T; Cooper TB; Tamminga CA
    J Neural Transm (Vienna); 1997; 104(1):97-104. PubMed ID: 9085197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral dyskinesias and morphological changes in rat striatum during long-term haloperidol administration.
    Andreassen OA; Meshul CK; Moore C; Jørgensen HA
    Psychopharmacology (Berl); 2001 Aug; 157(1):11-9. PubMed ID: 11512038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of chronic administration of sarizotan, 5-HT1A agonist/D3/D4 ligand, on haloperidol-induced repetitive jaw movements in rat model of tardive dyskinesia.
    Rosengarten H; Bartoszyk GD; Quartermain D; Lin Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):273-9. PubMed ID: 16229932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between chronic amphetamine and neuroleptic treatments on oral behavior in rats.
    Levy AD; Ellison GD
    Psychopharmacology (Berl); 1987; 93(2):218-22. PubMed ID: 3122254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basal ganglia GABAA and dopamine D1 binding site correlates of haloperidol-induced oral dyskinesias in rat.
    Shirakawa O; Tamminga CA
    Exp Neurol; 1994 May; 127(1):62-9. PubMed ID: 8200438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral administration of haloperidol at clinically recommended doses elicits smaller parkinsonian effects but more tardive dyskinesia in rats.
    Shireen E; Naeem S; Inam QU; Haleem DJ
    Pak J Pharm Sci; 2013 Mar; 26(2):271-6. PubMed ID: 23455196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
    Iderberg H; McCreary AC; Varney MA; Kleven MS; Koek W; Bardin L; Depoortère R; Cenci MA; Newman-Tancredi A
    Exp Neurol; 2015 Sep; 271():335-50. PubMed ID: 26037043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of chronic administration of haloperidol and the atypical neuroleptics, clozapine and raclopride, in an animal model of tardive dyskinesia.
    See RE; Ellison G
    Eur J Pharmacol; 1990 Jun; 181(3):175-86. PubMed ID: 2384130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Oral dyskinesia in rats after a single administration of haloperidol combined with GABA-linoleamide. A model of dyskinesia in man].
    Vamvakides A
    Agressologie; 1989 Feb; 30(2):89-91. PubMed ID: 2735495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.